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Abstract
Haploinsufficiency of CHD7 (OMIM# 608892) is known to cause CHARGE syndrome (OMIM#
214800). Molecular testing supports a definitive diagnosis in approximately 65%–70% of cases.
Most CHD7 mutations arise de novo, and no mutations affecting exon-7 have been reported to
date. We report on an 8-year-old girl diagnosed with CHARGE syndrome that was referred to our
laboratory for comprehensive CHD7 gene screening. Genomic DNA from the subject with a
suspected diagnosis of CHARGE was isolated from peripheral blood lymphocytes and
comprehensive Sanger sequencing, along with deletion/duplication analysis of the CHD7 gene
using multiplex ligation-dependent probe amplification (MLPA), was performed. MLPA analysis
identified a reduced single probe signal for exon-7 of the CHD7 gene consistent with potential
heterozygous deletion. Long-range PCR breakpoint analysis identified a complex genomic
rearrangement (CGR) leading to the deletion of exon-7 and breakpoints consistent with a
replicative mechanism such as fork stalling and template switching (FoSTeS) or microhomology-
mediated break-induced replication (MMBIR). Taken together this represents the first evidence
for a CHD7 intragenic CGR in a patient with CHARGE syndrome leading to what appears to be
also the first report of a mutation specifically disrupting exon-7. Although likely rare, CGR may
represent an overlooked mechanism in subjects with CHARGE syndrome that can be missed by
current sequencing and dosage assays.
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INTRODUCTION
CHARGE association is the acronym for Coloboma of the eyes, Heart defect, Atresia
choanae, Retarded growth and development, Genital abnormality, and Ear anomaly –
anomalies found more frequently together than would be predicted if seen by chance
occurrences as the probabilities of individual birth defects. The pattern of abnormalities
differs among individuals with CHARGE syndrome due to clinical variability, and infants
may often present with life-threatening medical conditions [Issekutz et al., 2005].
Clinical diagnosis of CHARGE syndrome is based on a combination of major and minor
diagnostic criteria [Verloes, 2005]. However, molecular testing of the CHD7 gene is able to
confirm the diagnosis in the majority of cases. CHD7 is a chromodomain helicase DNA
binding protein 7 that plays a role in transcription activation and repression by chromatin
remodeling. The Chromodomain Helicase DNA-binding (CHD) protein family consists of
nine members that can be subdivided into three subfamilies, all containing two
chromodomains, or domains modifying the chromatin organization, which are located
proximally to the N-terminus of the protein, followed by a more distal sucrose non
fermenting (SNF2)-like ATP-dependent catalytic helicase motif [Hall and Georgel, 2007;
Marfella and Imbalzano, 2007]. CHD7 is highly conserved across species and orthologs
have been identified in both vertebrates and invertebrates such as Xenopus, zebrafish,
mouse, and chicken [Aramaki et al., 2007; Bajpai et al., 2010; Bosman et al., 2005]. The
CHD7 gene is associated with the majority of CHARGE syndrome cases and consists of 38
exons, of which the first is noncoding, and spans 188kb of genomic DNA on chromosome
8q12.1–q12.2 [Vissers et al., 2004; Layman et al., 2010; Janssen et al., 2012].
Sequence and deletion/duplication analysis of the CHD7 coding region detects heterozygous
mutations in 65%–80% of individuals with CHARGE syndrome. The majority are single
nucleotide variant (SNV) alleles, including nonsense, frameshift deletions, or missense
CHD7 mutations [Vissers et al., 2004; Layman et al., 2010; Janssen et al., 2012]. CHD7
mutations in human subjects are distributed along the entire coding sequence and do not
appear to be correlated with specific aspects of the clinical phenotype [Vissers et al., 2004;
Layman et al., 2010; Janssen et al., 2012]. However, no mutations have been found in
exon-7 (56bp), which represents the boundary of the first chromodomain [Vissers et al.,
2004; Layman et al., 2010; Janssen et al., 2012]. Most CHD7 mutations identified thus far
have been shown to have arisen de novo although germline mosaicism has been reported in
families with multiple affected siblings [Vissers et al., 2004; Layman et al., 2010; Janssen et
al., 2012].
MATERIALS AND METHODS
Patient Report
The patient is an 8-year-old Caucasian female delivered at 35-weeks gestation via cesarean
due to fetal inactivity and fluctuating heart rate. She presented at birth with multiple
congenital anomalies including tetralogy of Fallot (TOF), for which she underwent a
Blalock-Taussig shunt procedure at 12 hours of life followed by complete surgical repair at
16 months of age. In addition to TOF, other congenital heart malformations included a right
aortic arch with a vascular ring and a cleft mitral valve. Immediately after birth the patient
developed significant respiratory problems, which required intubation and constant
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monitoring in the neonatal intensive care unit (NICU) where she remained for more than 2
months. At two weeks of age, facial dysmorphic features and the overall clinical
presentation appeared to be most consistent with typical CHARGE syndrome. In addition to
the conotruncal defects, the patient presented with bilateral retinal colobomas apparently
without major visual impairment. The patient also underwent Auditory Brainstem Response
(ABR) testing that identified normal conduction of auditory stimuli in the right ear (wave I =
1.83msec; wave II = 4.39msec; wave V = 6.07msec; wave III–V latency difference = 1.69;
wave I–V latency difference = 4.25) associated with moderate sensorineural hearing loss
(30decibel at 500Hz; 55decibel at 4000Hz) in her right ear. The ABR test for the left ear
failed to yield reliable measurements or response suggesting severe to profound primary
sensorineural hearing loss in her left ear requiring hearing aids for both ears. Computed
tomography (CT) scan analysis revealed complex congenital deformities of both middle and
inner ears on each side, characterized by apparent anterior mallear fusion, vestibule
hypoplasia with hypoplasia/absence of semicircular canals, cochlear dysplasia and an
enlarged vestibular aqueduct on the left, and possible cochlear dysplasia on the right without
a definitely enlarged vestibular aqueduct. There is also partial opacification of the middle
ears and mastoids.
The patient was born with choanal atresia and an H-type tracheo-esophageal fistula, both of
which were surgically repaired although the patient required enteral nutrition via
gastrostomy tube (G-tube). The patient also presented with severe gastroesophageal reflux,
which required a Nissen fundoplication. In addition, she presented with duodenal atresia in
two sites, which was surgically repaired, followed by a duodenoplasty at 7 years of age. She
developed osteoporosis and demonstrated motor, speech, and cognitive delays, requiring
special education along with occupational, physical, and speech therapy. Prior to CHD7
analysis, the patient had a fluorescence in situ hybridization (FISH) study for 22q11.2
deletion, which was negative. The patient has also a healthy sibling, and the proband’s
family history is otherwise unremarkable for CHARGE syndrome, heart defects, or other
genetic syndromes.
GENETIC ANALYSIS
Genomic DNA from this individual was obtained after informed consent for clinical testing
of the coding sequence and exon/intron boundaries of the CHD7 gene (RefSeq:
NM_017780.3) and analyzed using polymerase chain reaction (PCR) and Sanger DNA
sequencing as previously described, along with multiplex ligation-dependent probe
amplification (MLPA) using a kit from MRC Holland (www.mlpa.com) in order to search
for intragenic deletions or duplications as previously published [Wincent et al., 2008, 2009].
Long fragment PCR product (~7.3Kb) flanking the deleted region was obtained using the
following primers: TGTTGCAGAAGGAATCTGGA (exon-7 intron/exon boundary
forward) and TGCTTTGCAAACTCATTCCA (Intron 4 forward),
CTGTCTGGGCCAGGTGTACT (Intron 7 reverse), ATGCCTGCTGGTCTGTTTCT
(Intron 6 forward) and GCTTGAGCCACCCCTATTTA (Intron 6 reverse),
TACCATTTCTCAAGTCAGGCCA (Intron 6/Intron 4 boundary reverse) linked to and M13
tail. Amplified junctional fragment PCR products were purified and sequenced as described
above. Computational analysis was employed to examine the CHD7 genomic sequence
encompassing the breakpoints observed in our patient sample.
RESULTS
Sequence analysis did not identify any changes that could be classified as disease-causing
while MLPA analysis, which was repeated on separate samples from the index case, showed
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consistently reduced signal for a single probe in exon-7, indicating a potential copy number
variant (CNV) and possible heterozygous deletion of exon-7 of the CHD7 gene (Fig 1A).
Neither pathogenic CNV nor single nucleotide variants (SNV) involving exon-7 has been
previously reported in patients with CHARGE syndrome (www.chd7.org). Given that the
possible deletion was suggested by a single probe and due to the proximity of the flanking
exons, we employed a long range PCR approach as a secondary method, necessary for
confirmation. Long fragment amplification and junctional PCR product sequencing
identified the breakpoint junctions in introns 6 and 7 (Figs 1B and 2C), consistent with a
deletion of approximately 4484 nucleotides, which includes exon-7. Furthermore, sequence
analysis of the PCR product encompassing the breakpoint junction revealed that
approximately 347 nucleotides from intron 4 (human reference sequence GRCh37/hg19:
chr8: 61711127–61711473) of the CHD7 gene were inserted between intron 6 and 7
breakpoints (Figs. 1B and 2C); all three distinct and usually separate genomic segments
were juxtaposed in a direct orientation, and microhomology (5bp and 2bp) was observed at
the breakpoint junctions (Figs. 1B and 2C). Samples from the unaffected parents and sib of
the index cases were tested and showed normal signal for the MLPA exon-7 probe of the
CHD7 gene (Fig 1A) and normal PCR fragment size (Figs. 2A–B). Taken together, these
data support a de novo heterozygous deletion of exon-7 of the CHD7 gene in our patient,
which is consistent with a clinical diagnosis of CHARGE syndrome.
Computational analysis of the CHD7 genomic sequence encompassing the breakpoint
identified regions of micro-homology (Fig 2C) consistent with this complex genomic
rearrangement having been generated by replicative mechanism such as FoSTeS/MMBIR
[Lee et al., 2007; Zhang et al., 2009; Hastings et al., 2009].
DISCUSSION
In this report, we provide the first evidence of a deletion of exon-7 of the CHD7 gene in an
individual with a clinical diagnosis of CHARGE syndrome as a result of a complex genomic
rearrangement consistent with a replicative mutational mechanism.13 In addition, this is the
first report that involves specifically a deletion of exon-7, which represents the distal
boundary of the first chromodomain of CHD7 [Vissers et al., 2004]. Interestingly, in the
vicinity of breakpoint one and two, there are two AluY sequence elements, and although the
rearrangements could not be explained by Alu-mediated recombinations, it has been recently
hypothesized that AluY elements could facilitate template switching and annealing via their
31-bp microhomology between replication forks and restarting (priming) DNA replication in
one of the multiple FoSTeS/MMBIR events that generated the complexity [Zhang et al.,
2009; Hastings et al., 2009]. Previously, a de novo Alu retrotransposition-mediated deletion
encompassing exons 8–12 of CHD7 was identified in a CHARGE syndrome subject [Udaka
et al., 2007].
The FoSTeS/MMBIR mechanism represents an aberrant pattern of DNA replication during
mitosis in which the active replication fork can stall and switch templates using
complementary microhomologous DNA template to anneal and initiate DNA replication
[Zhang et al., 2009]. Linearly, the replication forks could be parted by a significant genomic
fragment although the DNA bending could favor their physical vicinity, allowing the
utilization of the same replisome machinery. Therefore, the FoSTeS/MMBIR mechanism
may represent a significant source of structural variations in the human genome and cause of
human diseases, such as CHARGE.
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Figure 1. MLPA analysis and genomic structure encompassing exon 7
A) MLPA analysis of the proband and available first degree relatives. Filled symbol and
black arrow indicates the proband. Unfilled symbols indicate unaffected relatives. The red
arrow indicates the single probe with reduced signal in proband DNA. B) Genomic structure
of CHD7 encompassing exon 7. Filled in black are the exons, in light blue the sequence
composing the junctional fragment, while in red are the repetitive elements. Arrows indicate
the position of the primers employed for the long range PCR analysis.
Vatta et al. Page 7
Am J Med Genet A. Author manuscript; available in PMC 2014 December 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Vatta et al. Page 8
Am J Med Genet A. Author manuscript; available in PMC 2014 December 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Vatta et al. Page 9
Am J Med Genet A. Author manuscript; available in PMC 2014 December 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2. Multiplex PCR analysis of the wild type and mutant CHD7 alleles
A) Relative position of the primers designed for the amplification of the wild type CHD7
allele fragments (a) and for mutant CHD7 allele fragments (b). B) Electrophoretic analysis
of the multiplex PCR amplification along with the family pedigree. PCR fragment size is
indicated. C) Computational analysis and electropherograms of the sequences composing the
junctional fragment indicating the microhomology of the two breakpoints consistent with
FoSTeS/MMBIR (FoSTeS 1 and 2). The position numbering of the nucleotide sequence
refers to the genomic coordinates.
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